Table 1. Efficacy results of... | American Society of Hematology

Table 1.

Efficacy results of FDA-approved first- and second-generation BTK inhibitors

BTKi	N	Median lines of prior treatments (range)	ORR, %	CR, %	Median follow-up (mo)	Median duration of response (mo)	Median PFS (mo)	Median OS (mo)
Ibrutinib³	111	3 (1-5)	67	23	26.7	17.5	13	22.5
Acalabrutinib¹⁰	124	2 (1-5)	81	48	38.1	28.6	22	NR
Zanubrutinib¹	86	2 (1-4)	83	77.9	35.3	NR	33	NR

BTKi	N	Median lines of prior treatments (range)	ORR, %	CR, %	Median follow-up (mo)	Median duration of response (mo)	Median PFS (mo)	Median OS (mo)
Ibrutinib³	111	3 (1-5)	67	23	26.7	17.5	13	22.5
Acalabrutinib¹⁰	124	2 (1-5)	81	48	38.1	28.6	22	NR
Zanubrutinib¹	86	2 (1-4)	83	77.9	35.3	NR	33	NR